{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:50:42Z","timestamp":1762876242096},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.medcli.2020.06.057","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T12:08:42Z","timestamp":1598616522000},"page":"541-547","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Toxicities from immunotherapy: From clinical trials to real-world clinical practice"],"prefix":"10.1016","volume":"155","author":[{"given":"Mar","family":"Riveiro-Barciela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Trallero-Aragu\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Mart\u00ednez-Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Roca-Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Barreira-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2020.06.057_bib0305","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","article-title":"Antagonists of PD-1 and PD-L1 in cancer treatment","volume":"42","author":"Lipson","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0310","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.medcli.2020.06.057_bib0320","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.medcli.2020.06.057_bib0325","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.medcli.2020.06.057_bib0330","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0335","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medcli.2020.06.057_bib0340","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0345","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.06.057_bib0350","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.06.057_bib0355","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.06.057_bib0360","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0365","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","article-title":"Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy","volume":"31","author":"Lake","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.medcli.2020.06.057_bib0370","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0375","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","article-title":"Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies?","volume":"70","author":"Riveiro-Barciela","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0380","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","article-title":"Immunotherapy-related hepatitis: real-world experience from a tertiary centre","volume":"10","author":"Cheung","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0385","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0390","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.medcli.2020.06.057_bib0395","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0400","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.medcli.2020.06.057_bib0405","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.medcli.2020.06.057_bib0410","doi-asserted-by":"crossref","first-page":"e000278","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume":"3","author":"Geukes Foppen","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.medcli.2020.06.057_bib0415","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrgastro.2018.14","article-title":"Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management","volume":"15","author":"Samaan","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0420","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1111\/ajco.12651","article-title":"Infliximab for ipilimumab-induced colitis: a series of 13 patients","volume":"13","author":"Hillock","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0425","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0430","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0435","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"Kahler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.medcli.2020.06.057_bib0440","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.medcli.2020.06.057_bib0445","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.medcli.2020.06.057_bib0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0455","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2020.06.057_bib0460","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2020.06.057_bib0465","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0470","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors","volume":"42","author":"Mazarico","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.medcli.2020.06.057_bib0475","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0480","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1530\/JME-18-0002","article-title":"Novel cancer therapies and their association with diabetes","volume":"62","author":"Shariff","year":"2019","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0485","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medcli.2020.06.057_bib0490","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.medcli.2020.06.057_bib0495","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.medcli.2020.06.057_bib0500","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/imt-2016-0117","article-title":"Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment","volume":"9","author":"Cappelli","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.medcli.2020.06.057_bib0505","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0510","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2020.06.057_bib0515","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.medcli.2020.06.057_bib0520","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2020.06.057_bib0525","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.06.057_bib0530","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2020.06.057_bib0535","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2020.06.057_bib0540","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.medcli.2020.06.057_bib0545","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.medcli.2020.06.057_bib0550","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.06.057_bib0555","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.medcli.2020.06.057_bib0560","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.medcli.2020.06.057_bib0565","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.medcli.2020.06.057_bib0570","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.nmd.2018.11.012","article-title":"Clinical spectrum of neuromuscular complications after immune checkpoint inhibition","volume":"29","author":"Puwanant","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.medcli.2020.06.057_bib0575","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/cid\/ciy1025","article-title":"Inflammatory and infectious syndromes associated with cancer immunotherapies","volume":"69","author":"Fishman","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.06.057_bib0580","doi-asserted-by":"crossref","first-page":"101979","DOI":"10.1016\/j.ctrv.2020.101979","article-title":"Toxicity management with combination chemotherapy and programmed death 1\/programmed death ligand 1 inhibitor therapy in advanced lung cancer","volume":"85","author":"Hoffner","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.medcli.2020.06.057_bib0585","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.medcli.2020.06.057_bib0590","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.medcli.2020.06.057_bib0595","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","article-title":"Renal complications of immune checkpoint blockade","volume":"41","author":"Murakami","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.medcli.2020.06.057_bib0600","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775320305741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775320305741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T18:24:50Z","timestamp":1668104690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775320305741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0025775320305741"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2020.06.057","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicities from immunotherapy: From clinical trials to real-world clinical practice","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2020.06.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}